Document Type


Journal Title

ACS Chemical Biology

Publication Date





This Letter reports a family of novel antimicrobial compounds obtained by combining peptide library screening with structure-based design. Library screening led to the identification of a human LL-37 peptide resistant to chymotrypsin. This d-amino-acid-containing peptide template was active against Escherichia coli but not methicillin-resistant Staphylococcus aureus (MRSA). It possesses a unique nonclassic amphipathic structure with hydrophobic defects. By repairing the hydrophobic defects, the peptide (17BIPHE2) gained activity against the ESKAPE pathogens, including Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species. In vitro, 17BIPHE2 could disrupt bacterial membranes and bind to DNA. In vivo, the peptide prevented staphylococcal biofilm formation in a mouse model of catheter-associated infection. Meanwhile, it boosted the innate immune response to further combat the infection. Because these peptides are potent, cell-selective, and stable to several proteases, they may be utilized to combat one or more ESKAPE pathogens.

MeSH Headings

Amino Acid Sequence, Animals, Antimicrobial Cationic Peptides, Catheter-Related Infections, Disease Models, Animal, Drug Design, Enterococcus faecium, Humans, Hydrophobic and Hydrophilic Interactions, Male, Methicillin-Resistant Staphylococcus aureus, Mice, Inbred C57BL, Microbial Sensitivity Tests, Molecular Sequence Data, Pseudomonas aeruginosa, Staphylococcal Infections, Staphylococcus aureus, Structure-Activity Relationship




This ACS article is provided to You under the terms of this Standard ACS AuthorChoice/Editors’ Choice usage agreement between You and the American Chemical Society (“ACS”), a federally-chartered nonprofit located at 1155 16th Street NW, Washington DC 20036. Your access and use of this ACS article means that you have accepted and agreed to the Terms and Conditions of this Agreement. ACS and You are collectively referred to in this Agreement as “the Parties”).